Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors

NCT02611024 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT02611024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02611024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Lead sponsor
PharmaMar
Phase
Phase 1/2
Overall status
Completed
Start date
May 6, 2016
Completion date
July 1, 2025
Enrollment
316 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal carcinoma, endometrial carcinoma, epithelial ovarian carcinoma, gastric carcinoma, gastroenteropancreatic neuroendocrine tumor, glioblastoma, mesothelioma, neuroendocrine tumors, pancreatic adenocarcinoma, sclc, soft tissue sarcoma (excluding gist)